Table 5 Self-reported combination therapies used by severe asthma status in Argentina, Chile, Colombia, and Mexico, 2013–2015
Severe asthma | Non-severe asthma | p-value | Total | ||||
|---|---|---|---|---|---|---|---|
N | (%) | n | (%) | N | (%) | ||
ICS + LABA | 88 | 47.8 | 203 | 49.5 | 0.704 | 291 | 49.0 |
ICS only | 0 | – | 103 | 25.1 | < 0.001 | 103 | 17.3 |
ICS + LABA + Tiotropium | 8 | 4.3 | 0 | – | < 0.001 | 8 | 1.3 |
ICS + LABA + LTRA | 15 | 8.2 | 25 | 6.1 | 0.356 | 40 | 6.7 |
ICS + LABA + Xanthine | 0 | – | 2 | 0.5 | 1.000 | 2 | 0.3 |
ICS + LABA + Anti-IgE | 3 | 1.6 | 0 | – | 0.029 | 3 | 0.5 |
ICS + LTRA | 1 | 0.5 | 0 | – | 0.310 | 1 | 0.2 |
ICS + LABA + Antihistamine | 9 | 4.9 | 10 | 2.4 | 0.116 | 19 | 3.2 |
Other | 60 | 32.6 | 67 | 16.3 | < 0.001 | 127 | 21.4 |